Aadi

Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

Retrieved on: 
Sunday, March 17, 2024
TSC1, Ovarian cancer, AADI, Endometrial cancer, Perivascular epithelioid cell tumour, EEC, Cervical cancer, Patient, Neoplasm, Cancer, Trial of the century, University, SGO, MD, Malignancy, Society, Safety, Gynecologic Oncology (journal), TSC2, FDA, Glomus tumor, Aadi, Pharmaceutical industry

LOS ANGELES, March 17, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced patients in the AMPECT trial whose malignant perivascular epithelioid cell tumor (PEComa) had gynecologic origins experienced efficacy and safety consistent with the overall study population. The AMPECT trial formed the basis for the FDA approval of the company's nab-sirolimus, FYARRO®, for advanced malignant PEComa regardless of mutational status. This new subgroup analysis will be presented during an oral plenary at the Society of Gynecologic Oncology (SGO) Annual Meeting in San Diego, CA on March 17, 2024.

Key Points: 
  • The AMPECT trial formed the basis for the FDA approval of the company's nab-sirolimus, FYARRO®, for advanced malignant PEComa regardless of mutational status.
  • This new subgroup analysis will be presented during an oral plenary at the Society of Gynecologic Oncology (SGO) Annual Meeting in San Diego, CA on March 17, 2024.
  • "Overactivation of the mTOR pathway has been implicated in gynecological cancers," said Loretta Itri, MD, Chief Medical Officer at Aadi.
  • "nab-Sirolimus is a nanoparticle albumin-bound (nab) mTOR inhibitor under investigation in TSC1- and TSC2-mutated tumors as well as other mTOR-driven tumors.

Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations

Retrieved on: 
Thursday, December 14, 2023
Webcast, ID, Safety, Telephone, TSC1, Aadi, Patient, LOS, TSC2, Death, UPR, AADI, ORR, Pneumonitis, Cancer, CMO, Neoplasm, Pharmaceutical industry, Medical imaging, MD

LOS ANGELES, Dec. 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today reported results from a planned interim analysis on the first third of participants in the ongoing tumor-agnostic PRECISION1 trial evaluating nab-sirolimus in patients with TSC1 or TSC2 inactivating alterations. 

Key Points: 
  • "Our tumor agnostic PRECISION1 trial is designed to elucidate the impact of nab-sirolimus on cancers expressing inactivating alterations of TSC1 or TSC2, regardless of tumor type.
  • Nine different tumor types were enrolled in the TSC1 arm and 13 tumor types were enrolled in the TSC2 arm.
  • 80 patients are currently enrolled in the PRECISION1 trial, supporting the two-thirds interim analysis expected in the third quarter of 2024.
  • The Aadi management team is hosting a conference call and webcast today at 5:00 pm ET (2:00 pm PT) to discuss the interim results from the PRECISION1 trial.

Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)

Retrieved on: 
Tuesday, October 3, 2023
Acceleration, Option, Plan, Employment, Patient, Compensated emancipation, AADI, Pharmaceutical industry, Security (finance), Aadi

The award was granted pursuant to the terms of Dr. Lennon's employment agreement and as a material inducement to his joining Aadi as President and Chief Executive Officer in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The award was granted pursuant to the terms of Dr. Lennon's employment agreement and as a material inducement to his joining Aadi as President and Chief Executive Officer in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Compensation Committee of Aadi's Board of Directors, which is composed entirely of independent directors, approved, as a material inducement to Dr. Lennon entering into employment with Aadi, a grant of a nonstatutory stock option to purchase 490,000 shares of Aadi's common stock (the "Option") under the Plan.
  • The Option has a 10-year term and an exercise price per share equal to $4.30, the closing price as quoted on the Nasdaq Stock Market LLC on the Grant Date.
  • In addition, the Option may be subject to vesting acceleration upon certain qualifying termination events in accordance with the terms and conditions set forth in Dr. Lennon's employment agreement with Aadi.

Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer

Retrieved on: 
Monday, October 2, 2023
Interim, Columbia College (New York), Doctor of Philosophy, Cancer, McKinsey & Company, AADI, Molecular medicine, Patient, Weill Cornell Medicine, CFO, Biophysics, Growth, LOS, Rare, Cornell University, Disease, Pharmaceutical industry, Management, Novartis, Aadi

LOS ANGELES, Oct. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies with mTOR pathway alterations, today announced the appointment of Dave Lennon, Ph.D. as President and Chief Executive Officer.  Dr. Lennon brings more than twenty years of experience leading global biotechnology and pharmaceutical teams, with significant expertise in development and commercialization in oncology and non-oncology mTOR-driven diseases.  Dr. Lennon has also joined the Aadi Bioscience Board of Directors.  In connection with Dr. Lennon's appointment, Scott Giacobello, who served as Interim Chief Executive Officer and President since March 2023, will continue in his role as Chief Financial Officer. 

Key Points: 
  • Dr. Lennon has also joined the Aadi Bioscience Board of Directors.
  • In connection with Dr. Lennon's appointment, Scott Giacobello, who served as Interim Chief Executive Officer and President since March 2023, will continue in his role as Chief Financial Officer.
  • "Dave brings tremendous experience to Aadi.
  • Dr. Lennon joins Aadi Bioscience following his role as Chief Executive Officer and member of the board of directors at Satellite Bio, a privately held regenerative medicine company.

Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update

Retrieved on: 
Wednesday, August 9, 2023
TIP, NETS, Interim, Initiation, TSC1, Telephone, Mirati Therapeutics, Glomus tumor, Everolimus, Pancreas, ID, AADI, Lung, Sirolimus, ASCO, Endometrial cancer, TSC2, Patient, Investment, Cancer, Webcast, CFO, Growth, EEC, GI, Letrozole, Pharmacology, Safety, Pharmaceutical industry, Cryptocurrency, Aadi

LOS ANGELES, Aug. 9, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2023.

Key Points: 
  • LOS ANGELES, Aug. 9, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2023.
  • FYARRO net product sales were $6.2 million in the second quarter, reflecting growth of approximately 6% over Q1 2023 and 80% over the prior year quarter.
  • The Aadi management team is hosting a conference call and webcast today at 8:30 am ET (5:30 am PT) to provide a corporate update and discuss results for the second quarter 2023.
  • Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com .

Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
Abstract, Arm, AADI, ASCO, TSC2, Patient, Mucositis, Poster, Thrombocytopenia, Aadi, Safety, Fatigue, Pharmaceutical industry, Powder metallurgy, TSC1

LOS ANGELES, May 25, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced poster presentations at the 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL.

Key Points: 
  • LOS ANGELES, May 25, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced poster presentations at the 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL.
  • The abstracts associated with the poster presentations are now available on the ASCO meeting website .
  • Details of the poster presentations are below:
    A trial-in-progress poster detailing the PRECISION I trial will be presented.
  • Following the presentations at ASCO, the posters will be made available on the investor relations page of the Aadi website at www.aadibio.com .

Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
TIP, ASCO, Abstract, Aadi, AADI, Pharmaceutical industry, Powder metallurgy

LOS ANGELES, April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the acceptance of abstracts for poster presentation at the upcoming 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL.

Key Points: 
  • LOS ANGELES, April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the acceptance of abstracts for poster presentation at the upcoming 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL.
  • The presentations will consist of a company-sponsored Trials-in-Progress (TIP) update from the PRECISION 1 Phase 2 study and combination data of nab-sirolimus and pazopanib (PAZO) from an ongoing Investigator Initiated Trial.
  • The details of the poster presentations are below:
    Poster Session Display Date and Time: June 3, 2023, 1:15 PM-4:15 PM
    Poster Discussion Session Date and Time: June 3, 2023, 4:30 PM-6:00 PM
    Meeting details are available through the ASCO Annual Meeting planner Program | ASCO Annual Meeting Following Aadi's presentation at ASCO, the posters will be made available on the investor relations page of the Aadi website at www.aadibio.com

Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Friday, April 14, 2023
TIP, KRAS, Abstract (summary), AACR, Prevalence, Progression-free survival, RECIST, Ovary, NSCLC, Lung cancer, Perivascular epithelioid cell tumour, AADI, Trial of the century, TSC2, Patient, Poster, IRR, Aadi, Safety, Pharmaceutical industry, Medical imaging, Vaccine, TSC1

LOS ANGELES, April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL.

Key Points: 
  • LOS ANGELES, April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL.
  • nab-Sirolimus 100 mg/m2 will be given weekly intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle.
  • Full session and meeting details are available through the AACR Annual Meeting planner: AACR Annual Meeting 2023 | Meetings | AACR .
  • Each poster will be made available following the date of presentation at AACR, on the investor relations page of the Aadi website at www.aadibio.com

Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023

Retrieved on: 
Thursday, April 6, 2023
AACR, Aadi, AADI, Pharmaceutical industry

LOS ANGELES, April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will present three posters at the American Association for Cancer Research Annual Meeting (AACR) 2023, taking place April 14-19, 2023, in Orlando, FL.

Key Points: 
  • LOS ANGELES, April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will present three posters at the American Association for Cancer Research Annual Meeting (AACR) 2023, taking place April 14-19, 2023, in Orlando, FL.
  • The details of the poster presentations are below:
    Full session and meeting details are available through the AACR Annual Meeting planner: AACR Annual Meeting 2023 | Meetings | AACR .
  • Following Aadi's presentation at AACR, the posters will be made available on the investor relations page of the Aadi website at www.aadibio.com

Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors

Retrieved on: 
Monday, March 27, 2023
Nuvelo, ARCA, Biotechnology, Cancer, Pfizer, Bristol Myers Squibb, Perivascular epithelioid cell tumour, AADI, Harvard Medical School, Economics, Acquisition, TSC2, Patient, Peloton, Supergene, Growth, Merck, BMS, Merck & Co., Therapy, Cornell University, Medivation, Enzalutamide, Aadi, TSC1, Pharmaceutical industry

"We welcome Mohammad to our Board at an exciting time for Aadi, as we advance the development of FYARRO for unmet clinical needs beyond our approved indication of PEComa.

Key Points: 
  • "We welcome Mohammad to our Board at an exciting time for Aadi, as we advance the development of FYARRO for unmet clinical needs beyond our approved indication of PEComa.
  • Mohammad is a world-class clinical development leader in oncology and will be a great complement to our board and partner with our highly experienced team," said Caley Castelein, M.D., Aadi Board Chairman.
  • "Mohammad has been instrumental in the development of Medivation's Xtandi and Welireg (belzutifan), when at Peloton Therapeutics.
  • "I am excited to join Aadi's Board of Directors in their mission to unlock the potential of nab-sirolimus in addressing mTOR-driven diseases," said Dr. Hirmand.